Ripley94
09 Sep 2018
Marksman likes the chart ANCR… XXXX Hes pointed out moved through 50 day average, was recently a lot higher.
pharmaspecialist
15 May 2018
"A transformational year for Animalcare" I loved the following quote contained in today's results for AnimalcareJan Boone, Chairman of Animalcare Group plc, said: "2017 was a transformational year for Animalcare Group plc."I think most shareholders would agree with Mr. Boone that 2017 was indeed a transformational year for Animalcare and that is why the share price fell by over 50%. If only the transformation had not taken place and Animalcare had retained its independence.
pharmaspecialist
11 May 2018
Beware results on 15th May I think the concerns expressed by gamesinvestor and me almost a year ago have proven to be justified as it is now clear that Ecuphar has ruined Animalcare through its reverse takeover and this is reflected in the share price collapse and the many negative comments from investors on the various discussion boards. I am concerned to see Iain Menneer, Animalcare's former CEO, leaving the company suddenly a couple of weeks ago and the company's house broker commenting recently that it would be quite keen to see Animalcare's May (15th May) prelims to garner "further detail and granularity". It sounds as if even the house broker remains somewhat in the dark about how the company is doing. The results could of course be OK, it's just that there seems to be quite a bit of uncertainty here. However, the fundamental problem is that Ecuphar's business has unsatisfactory profit margins and I can see no evidence that Ecuphar's management know how to build a growth company.
pharmaspecialist
26 Jun 2017
Lukewarm on Ecuphar deal I think today's share price fall is an appropriate response to the Ecuphar transaction. Animalcare was doing fine without Ecuphar and its profit margins are better than those of Ecuphar and I don't buy the argument that big is better. It seems to me that both Animalcare and Ecuphar need to develop the regulatory expertise to enter the huge US market and this merger does not help in that regard and has a weak strategic rationale. As a shareholder, I would not support this merger.
pharmaspecialist
09 Jan 2017
Trading update very encouraging Very pleased to see that the company's financial performance is better than expectations. This is all the more impressive as Animalcare continues to invest significant sums in new product development and continues to have a strong balance sheet. I would suggest that today's share price rise is justified.My guess is that the company will continue to expand its range of products over the next five or so years and will then sell out to a larger company able to exploit many of Animalcare's products in the US, but this is of course just speculation.
II Editor
09 Dec 2016
NEW ARTICLE: Quiet ambition justifies juicy valuation "I'm going to get drawn into a whinge today, because I drove all the way to York for LSE:ANCR:Animalcare's AGM, mostly to find out how much it has agreed to pay its two executive directors. It is far from clear, at least to me, from the company's ..."[link]
mcescher
30 Mar 2016
Solid dividend player with healthy balance sheet. At least that is the view on here [link]
IOMINVESTCOM
26 Feb 2016
Re: Paul Scott's view Sold entire position for 27% profit
IOMINVESTCOM
21 Jan 2016
Paul Scott's view Share price: 203p (down 1.0% today)No. shares: 21.1mMarket cap: £42.8mTrading update - this RNS was also released yesterday. The company is a supplier of veterinary medicines. Note from the usual Stockopedia graphics on the right that it has high quality scores - in particular an excellent operating profit margin, indicating pricing power.Also note that it has a high StockRank of 97.Ed has explained in the past that a high StockRank is no guarantee of success, but picking a basket of high StockRank shares should, over time, out-perform a basket of low StockRank shares, and the performance stats validate that.So personally I always get a warm glow when a share that appeals to me on fundamentals also has a high StockRank - it's almost like having a robot friend that is checking my work & giving me a reasonableness check. I try to keep low StockRank shares to a minimum in my portfolio, as the odds of success are lower, so selection has to be very careful, and higher conviction, to make me take the additional risk.Trading in H1 (to 31 Dec 2015) sounds OK, if unexciting - revenue up 2.7% to £7.1m, although that rises to 5.6% if a one-off £0.2m sale in the prior year is excluded.What concerns me is that the PER has risen from about 12 in 2014, to 17.4 today. Therefore the share price appreciation since I last looked at it in Oct 2014 has been all about expansion of the earnings multiple, rather than the business doing much in terms of growth.This is a general problem with small caps. We used to be able to buy good companies on a PER of about 12. Now we have to pay 15-20 for similar companies. Maybe that is a function of ultra-low interest rates for an extended period? Assets become inflated in price. Remember the concept of mean reversion - what goes up will eventually come down again.Cash - this has risen to £6.1m, and the historic figures show nice cash generation, with the company hoarding a growing cash pile. Cash represents 14.3% of the market cap, so it's fairly significant. It would be interesting to find out what the company intends doing with its cash pile - acquisitions, or a special divi perhaps? Given its stable, and high operating margin, the company doesn't need to hoard cash, and could actually run with say £4m or more of net debt. So there is scope to release about £10m in cash for other purposes, in my view - giving potential upside for investors.New products - details are given about new products being developed, so I think this is the key area to research, if looking into this company in more detail. If it has good growth in the pipeline, then the shares might end up looking cheap in a year or two perhaps? I like the concept of cash generative companies funding their own growth, through new products, or acquisitions.Dividends - a nice progression of well-covered divis has been paid out in recent years. The forecast yield is currently about 3%.Outlook - sounds confident;Following the solid trading performance in the first half, particularly across the Licensed Veterinary Medicines and Animal Welfare Product groups, the Board remains confident about the prospects and outcome for the full year.My opinion - this is only a brief review, as usual, so more in-depth research is always necessary. On the face of it, this share looks perhaps priced about right, or possibly a little too expensive? It's difficult to justify a PER of 17 for a company with pedestrian growth, although adjusting out the cash would bring the PER down to nearer 15, not outrageously high, but hardly a bargain.If you think the new products are set to generate significant growth in profit, then it might be worth pursuing.It looks a good company, and has a lot of features I like - high profit margin, decent & growing divis, net cash, stable & predictable profitability, I'm just not convinced the current valuation stacks up.Another point to consider is whether customers might squeeze its m
II Editor
16 Oct 2015
NEW ARTICLE: Animalcare: Point of accelerated growth nears "Pet medicine and supplies distributor Animalcare remains highly profitable as it invests in the reformulation of well-established generic medicines to make them more marketable. In full-year results to 30 June 2015, Animalcare lifted ..."[link]
IOMINVESTCOM
14 Oct 2015
Re: Target 2.45 Market has re-acted very bullish to these results and good to see Broker share price target in this example has been reached today. It will be interesting to see if Panmure Gordon revise this 2.45 target based on today's figures.Currently paper gain 50%GLTA
II Editor
14 Oct 2015
NEW ARTICLE: Animalcare in great health "LSE:ANCR:Animalcare sells lots of pet drugs and ID microchips to vets up and down the country. Decent growth over the past few years has ignited interest in the shares, and latest full-year results triggered a 6% rally Wednesday. Broker Panmure ..."[link]
IOMINVESTCOM
24 Feb 2015
Target 2.45 Veterinary medicines business Animalcare (ANCR) grew pre-tax profits by 28% to 1.76 million pounds in the six months to December, prompting it to hike the interim dividend by 20% to 1.8p per share. Driving the numbers was strong revenue growth of 10.6% in the Licensed Veterinary Medicines business and an increase in margins. Cash generation was stronger than expected, with the firm ending the period with net cash of just over 5 million pounds. Broker Panmure Gordon has a 245p target on the shares, which rose by 7p to 192p.
IOMINVESTCOM
22 Jan 2015
Edison - Companion animals are good for the company [link]
IOMINVESTCOM
23 Dec 2014
Started a small position Bought some of these on 8/12 @ 1.57 after reading high profile fund manager has been building their stake and that the year long downtrend on the charts has firmly been broken.Soon to challenge previous highs around 1.78.Maybe a NAP for 2015 somewhere!GLTA
